You see, in my head, my resolutions have already borne plenty of success. In reality, crippling fatigue and facial nerve pain have halted even more tasks, projects and mighty dreams, but, LGO*. Source: irelandms.com
Category: Multiple Sclerosis Research
Natalizumab now recommended in England to treat hard-to-control MS
The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service (NHS) in England, with decisions also influencing NHS…
Mothers with MS symptoms may face longer waits for a diagnosis, study finds
Women with multiple sclerosis (MS) who have children experience significantly longer waits before receiving a diagnosis than women without children, according to a new U.S. study. On average, each child was associated with an additional 1.28-year delay in diagnosis. The delay was even longer among women whose symptoms began during their reproductive years and among…
Metformin trial failure?
Tweet Metformin has become flavour of the month trial and there are numerous studies ongoing or recently completed. Here they have done a study of metformin plus beta interferon and say that there was no evident benefit….Should we fear for Octopus the MS trial in UK and Australia looking at metformin? However, here they split…
International experts chart global strategy to prevent multiple sclerosis
The post International experts chart global strategy to prevent multiple sclerosis appeared first on MS Australia. Source: www.msaustralia.org.au
Foralumab nasal spray continues to show long-term safety in SPMS: Data
Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple sclerosis (MS), Alzheimer’s disease, and multiple system atrophy….
New Hopeful Year of 2026
Happy first Monday of 2026! The New Year is already off to an unusual start. Before I delve into too much detail, 2025 is now in our past, which I am thankful for, as it was not the best year. Of course, the past several years have been slightly challenging and frustrating. A few of the…
Breakthrough Again
Tweet I was asked what I thought of the MS in the media report. “Two new subtypes of MS found in ‘exciting’ breakthrough…Scientists have discovered two new subtypes of MS paving the way personalised treatments and better outcomes for patients” I choose not to comment on these papers becuase of the agro it causes, but…
New news from NICE..They are deluded to think this is anything new
Tweet There is new news that people with highly active MS have a new choice…they can have a biosimilar of Tysabri called Tyruko…whoopee-do. NICE recommend it because it is cheaper but in reality they are more or less the same, so why waste cash, but it is not really more choice, it is access to…
How I remember 2025 (without overdoing it)
This post would never end if I shared every photo from 2025. And, honestly, that wouldn’t tell the real story anyway. So, I gave myself a boundary: two photos per month. Not too little, not too much. Just enough to capture the moments that made me pause, laugh, adapt or feel especially grateful. This is…